We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Enigma Diagnostics Appoints Dr Mo Aslam as Programme Director

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Enigma Diagnostics, the life sciences company developing molecular diagnostics systems, has announced the appointment of Dr Mo Aslam as Programme Director.

In this role, Dr Aslam will be responsible for all ongoing development programmes within Enigma, with particular emphasis on Enigma’s rapid diagnostics systems in three key areas:

• Point-of-care clinical diagnostics for infectious disease detection and screening.

• In-field veterinary applications for detection of infectious diseases affecting livestock, birds and wildlife.

• Defence and security applications for the detection of biological threats (bacteria and viruses) in the field, at   national borders and at other crucial sites.

Dr Aslam is a senior manager with extensive project and programme management experience in healthcare R&D and manufacturing gained from a 22-year career in the life sciences sector. During this time, Dr Aslam has specialised in managing product development teams using Six Sigma methodologies to support new and existing product launches from inception to commercialisation, including clinical trials, regulatory affairs and manufacturing.

He has been involved in the successful development and launch of a range of products in the medical diagnostics and devices area as well as in improving the speed of the product development process.

Most recently, Dr Aslam was a consultant to Novartis Vaccines, helping to introduce project management and process improvement methodologies across the company.

Before that, he spent five years as Projects Group Manager at Abbott Diabetes Care, a developer of medical devices, and ten years at Ortho-Clinical Diagnostics, a Johnson & Johnson company.

John McKinley, Executive Chairman, said: “Mo has excellent experience that will be of significant benefit to Enigma as the company moves more quickly into its product commercialisation phase. The successful in-field trials of our first rapid molecular diagnostics platform instrument have provided us with great confidence in its ability to perform and Mo will play a crucial role in developing the range of optimised products for this and future instrument platforms across the clinical, veterinary and defence markets we currently target.”